Elektrofi Raises $112M in Series C Funding to Revolutionize Biologic Therapy Delivery

Elektrofi, a pioneering biopharmaceutical formulation technology company based in Boston, is thrilled to announce that it has successfully raised $112 million in its latest funding round. This significant investment will accelerate the development and commercialization of its groundbreaking Hypercon™ technology platform, which is poised to redefine how biologic therapies are administered. By resolving the challenges associated with traditional intravenous delivery methods, Elektrofi’s innovative hyper concentration microparticle technology empowers patients to self-administer life-changing monoclonal antibodies and therapeutic proteins in the comfort of their homes. This paradigm shift not only enhances convenience and adherence to treatment but also aligns with Elektrofi’s commitment to a patient-centered healthcare approach. With this funding, Elektrofi will further its collaborative efforts with strategic partners to bring more subcutaneous biologic therapies to market, ultimately making a positive impact on the lives of patients worldwide. As the company continues to innovate and push the boundaries of biopharmaceutical delivery, it reaffirms its mission of Formulating the Future of Biologics™. For more information about Elektrofi and its vision for a healthier world, please visit www.elektrofi.com.